ArticleGlycoconjugate journal2015
Multiple lectin assays for detecting glyco-alteration of serum GP73 in liver diseases.
Article in Glycoconjugate journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 21 citations in OpenAlex.
- Spatial omics-based machine learning algorithms for the early detection of hepatocellular carcinoma.Communications medicine · 2024Article
- Deciphering disease through glycan codes: leveraging lectin microarrays for clinical insights.Acta biochimica et biophysica Sinica · 2024Review
- Lectins as versatile tools to explore cellular glycosylation.European journal of histochemistry : EJH · 2024Article
- Lectin Histochemistry: Historical Perspectives, State of the Art, and Future Directions.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Abnormal ECA-Binding Membrane Glycans and Galactosylated CAT and P4HB in Lesion Tissues as Potential Biomarkers for Hepatocellular Carcinoma Diagnosis.Frontiers in oncology · 2022Article
- Multiple lectin assays in detecting glycol-alteration status of serum NRG1 in papillary thyroid cancer.Translational cancer research · 2021Article
- MiR-559 targets GP73 to suppress proliferation and invasion of hepatocellular carcinoma in vitro.The Kaohsiung journal of medical sciences · 2020Article
- Serum profile of low molecular weight fucosylated glycoproteins for early diagnosis of hepatocellular carcinoma.Oncology letters · 2020Article
- Application of Lectin Microarrays for Biomarker Discovery.ChemistryOpen · 2020Review
- Golgi protein 73 and its diagnostic value in liver diseases.Cell proliferation · 2019Review
- A sensitive three monoclonal antibodies based automatic latex particle-enhanced turbidimetric immunoassay for Golgi protein 73 detection.Scientific reports · 2017Article
- A procedure for the analysis of site-specific and structure-specific fucosylation in alpha-1-antitrypsin.Electrophoresis · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Serum GP73 is a functional resident Golgi type II membrane protein with three potential N-glycosylation sites. In this study, we used multiple lectin assays to analyze glycan patterns of serum GP73 and evaluated its diagnostic value for distinguishing hepatocellular carcinoma (HCC) from liver cirrhosis (LC). Firstly, Antibody overlay lectin microarray and lectin blot were performed to observe altered glycans of GP73. Fucosylated structures were found to increase significantly in LC compared with HCC patients. Then, AAL ELISA assay using ELISA Index was utilized to measure fucosylation level of GP73 on its protein level (Fuc-GP73). ELISA Indices of 54 LC and 54 HCC patients was obtained and the area under the ROC curve (AUC) was 0.807 with a sensitivity of 85.2% and a specificity of 63.0% (cutoff of 3.182). In addition, combining Fuc-GP73 and AFP-L3 greatly improved the diagnostic accuracy (AUC = 0.953) and the diagnostic values were 94.4% sensitivity at 88.9% specificity. These data indicated that multiple lectin assays could contribute to pre-clinical evaluation of focused glycoprotein and Fuc-GP73 could act as a potential glycobiomarker complementary to AFP-L3 for discrimination of HCC from LC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.